U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06796231) titled 'Efficacy of PD-1 Monoclonal Antibody in the Treatment of Phaeohyphomycosis' on Nov. 16, 2024.
Brief Summary: The main objective was to evaluate the clinical efficacy of PD-1 inhibitor (PD-1 monoclonal antibody) in the treatment of skin and subcutaneous mucocytosis infection, including the comparison of immune cell groups before and after treatment, the changes in the proportion of CD4+T cells and CD8+T cells, and the changes in the inflammatory cytokines of the serum after co-culture of human peripheral blood mononuclear cells (PBMC) with fungi before and after treatment. The improvement of lesions and the relief of symptoms. The se...